Search
for
Sort by
Research
120-150 / 1000+ resultsresearch Sex- or Gender-specific Differences in the Clinical Presentation, Outcome, and Treatment of SARS-CoV-2
Men face more severe COVID-19 outcomes, while women are more likely to have long-term symptoms.
research Non‐invasive instrumental examinations of cutaneous, adnexal and mucosal manifestations after SARS‐COV‐2 infection in adult and children
Skin and mucosal issues can occur after COVID-19 in adults and children.
research Olive oil regenerates the hair lost during the alopecia complication caused through SARS Co-2 infection as well as with vaccination
Olive oil can help regrow hair lost due to COVID-19 or vaccination.
research Neurological post‐acute sequelae of SARS‐CoV ‐2 infection
Long COVID affects over half of COVID-19 survivors, causing a range of symptoms like fatigue and neurological issues, with no specific treatment yet.
research Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management
Hair loss is a frequent long-term effect of COVID-19, and oral minoxidil is the most common effective treatment.
research Male balding as a major risk factor for severe COVID-19: A possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals
Severe male balding may increase the risk of serious COVID-19, and treatments that reduce androgens or block a specific enzyme might help protect these individuals.
research Ultrastructural evidence for anagen hair follicle infection with SARS‐CoV ‐2 in early‐onset COVID ‐19 effluvium
COVID-19 may cause early hair loss by infecting hair follicles.
research A case of telogen effluvium followed by alopecia areata after SARS‐CoV ‐2 infection
Hair loss occurred after a COVID-19 infection.
research Diffused alopecia followed by severe acute respiratory syndrome coronavirus-2 infection
A woman's hair loss improved with treatment after a COVID-19 infection.
research Androgen sensitivity gateway to COVID ‐19 disease severity
Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.
research Racial variations in COVID‐19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti‐androgens a potential treatment for COVID‐19?
Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.
research Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men
Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
research The role of androgens in COVID-19
Higher androgen levels might make COVID-19 worse, especially in men.
research The Double Edge Sword of Testosterone’s Role in the COVID-19 Pandemic
Testosterone may influence COVID-19 severity and outcomes.
research Clinical symptoms of hyperandrogenic women diagnosed with COVID‐19
Women with high androgen levels may have more severe COVID-19 symptoms.
research Hormonal trends in patients suffering from long COVID symptoms
Long COVID patients may have hormonal imbalances linked to their symptoms.
research Testosterone in COVID-19: An Adversary Bane or Comrade Boon
Testosterone's effects on COVID-19 are unclear and need more research.
research Relationship between betacoronaviruses and the endocrine system: a new key to understand the COVID-19 pandemic—A comprehensive review
Betacoronaviruses, like COVID-19, may cause hormone system dysfunction and affect disease susceptibility and severity.
research COVID ‐19 induced telogen effluvium
COVID-19 may cause temporary hair loss in some people.
research Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review
COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
research Are sex hormones promising candidates to explain sex disparities in the COVID-19 pandemic?
Sex hormones like estrogen and testosterone may affect COVID-19 severity differently in men and women, potentially influencing prevention and treatment strategies.
research Do Anti-androgens Have Potential as Therapeutics for COVID-19?
Anti-androgens might help reduce COVID-19 severity in men.
research The probable destructive mechanisms behind COVID-19 on male reproduction system and fertility
COVID-19 may harm male fertility and damage the reproductive system.
research Immuno-Endocrinology of COVID-19: The Key Role of Sex Hormones
Sex hormones may affect COVID-19 severity, with estrogen possibly reducing risk and testosterone potentially increasing it.
research The secret identities of TMPRSS2: Fertility factor, virus trafficker, inflammation moderator, prostate protector and tumor suppressor
TMPRSS2 helps viruses enter cells and protects the prostate from inflammation-related cancer.
research Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy
Androgen deprivation therapy might be better for preventing COVID-19 than treating it.
research Alopecia areata and subsequent Marie Antoinette syndrome following COVID-19 infection and vaccination: A case report
COVID-19 infection and vaccination may trigger hair loss and rapid hair whitening.
research Risks of alopecia areata in long COVID: Binational population‐based cohort studies from South Korea and Japan
COVID-19 increases the risk of hair loss, but vaccination can reduce this risk.